China SXT Pharmaceuticals (SXTC) Total Current Liabilities (2018 - 2025)

China SXT Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $6.0 million for Q3 2025.

• In Q3 2025, Total Current Liabilities fell 61.94% year-over-year to $6.0 million; the TTM figure through Sep 2025 stood at $6.0 million (down 61.94% YoY), while the FY2025 annual figure was $6.0 million, down 32.46% from the prior year.
• Total Current Liabilities was $6.0 million for Q3 2025 at China SXT Pharmaceuticals, down from $6.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.6 million in Q1 2021 to a low of $6.0 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $11.2 million across 5 years, with a median of $9.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 70.26% in 2024, then sank 61.94% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $8.9 million in 2021, then declined by 17.87% to $7.3 million in 2022, then rose by 26.17% to $9.2 million in 2023, then surged by 70.26% to $15.7 million in 2024, then tumbled by 61.94% to $6.0 million in 2025.
• The last three Total Current Liabilities figures came in at $6.0 million (Q3 2025), $6.0 million (Q1 2025), and $15.7 million (Q3 2024), per Business Quant data.